Eculizumab in Pediatric and Adult Participants with Atypical Hemolytic Uremic Syndrome (aHUS) in China
Study Identifier:
D7413C00001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Study Complete
Study Details
Medical Condition
- Atypical Hemolytic Uremic
Study Drug
- Drug: Eculizumab
Date
Jul 2023 - May 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 0 - 99 Years
Requirements Information
Sex
Female & Male
Age
0 - 99 Years
Study Details
Medical Condition
- Atypical Hemolytic Uremic
Study Drug
- Drug: Eculizumab
Date
Jul 2023 - May 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 0 - 99 Years years
Requirements Information
Protocol Summary
This is a Phase 3b, open-label, single-arm, multicenter study to evaluate the efficacy and safety of eculizumab in participants with atypical hemolytic uremic syndrome (aHUS) in China
Trial Locations
Location
Status
Location
Research Site
Changsha, Unmapped, 410007
Status
Completed
Location
Research Site
Guangzhou, Unmapped, 510062
Status
Withdrawn
Location
Research Site
Nanchang, Unmapped, 330006
Status
Withdrawn
Location
Research Site
Wuhan, Unmapped, 430030
Status
Completed
Location
Research Site
nanjing, Unmapped, 210002
Status
Withdrawn
Location
Research Site
Suzhou, Unmapped, 215002
Status
Withdrawn